Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Donald Notman Sells 6,301 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 6,301 shares of Ocular Therapeutix stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $7.84, for a total value of $49,399.84. Following the completion of the transaction, the insider now owns 204,563 shares of the company’s stock, valued at approximately $1,603,773.92. This represents a 2.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Donald Notman also recently made the following trade(s):

• On Tuesday, February 4th, Donald Notman sold 11,119 shares of Ocular Therapeutix stock. The shares were sold at an average price of $7.81, for a total value of $86,839.39.

Ocular Therapeutix Trading Down 6.0 %

Shares of Ocular Therapeutix stock opened at $7.64 on Friday. Ocular Therapeutix, Inc. has a 52 week low of $4.06 and a 52 week high of $11.77. The stock’s fifty day moving average is $8.57 and its two-hundred day moving average is $9.01. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on OCUL shares. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, December 3rd. Scotiabank began coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Ocular Therapeutix currently has an average rating of “Moderate Buy” and an average target price of $16.71.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Assenagon Asset Management S.A. purchased a new stake in Ocular Therapeutix in the 3rd quarter valued at about $24,584,000. Charles Schwab Investment Management Inc. raised its stake in shares of Ocular Therapeutix by 146.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock valued at $9,661,000 after acquiring an additional 660,080 shares in the last quarter. Braidwell LP boosted its holdings in shares of Ocular Therapeutix by 36.3% in the third quarter. Braidwell LP now owns 2,239,770 shares of the biopharmaceutical company’s stock valued at $19,486,000 after purchasing an additional 596,000 shares during the period. Polar Asset Management Partners Inc. bought a new position in Ocular Therapeutix in the third quarter worth approximately $4,288,000. Finally, FMR LLC increased its holdings in Ocular Therapeutix by 7,098.7% during the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock worth $3,779,000 after purchasing an additional 428,335 shares during the period. 59.21% of the stock is currently owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.